Isolation of the oncogene and epidermal growth factor-induced transin gene: complex control in rat fibroblasts.
Various oncogenes or epidermal growth factor (EGF) induce transcription of a 1.9-kilobase RNA (transin RNA) in rat fibroblasts. The induction by EGF can be blocked by cycloheximide. Thus the response of the transin gene to EGF appears to require de novo protein synthesis. Transin RNA induction is specific to EGF, as neither insulin, platelet-derived growth factor, fibroblast growth factor, nor transforming growth factor beta could elicit the same response. However, transforming growth factor beta could block the EGF induction of transin RNA. Whereas the calcium ionophore A23187 and the tumor promoter TPA, either alone or administered together, did not increase transin RNA levels, TPA could synergise with a serum factor to effect such an increase. Dibutyryl cyclic AMP also induced transin RNA. Treatment of cells with the microfilament-disrupting agent cytochalasin B, but not the microtubule-disrupting agent colcemid, resulted in an increase in transin RNA levels, suggesting a role for the cytoskeleton in control of transin gene expression. The transin RNA does not contain repeated sequences and appears to be encoded by a single-copy gene. The protein sequence encoded by the last four exons of the transin gene shows some homology to two regions of the heme-binding protein hemopexin.
D000818:Animals; D001483:Base Sequence; D002460:Cell Line; D004247:DNA / Q000032:analysis / Q000235:genetics / Q000302:isolation & purification*; D004262:DNA Restriction Enzymes; D004815:Epidermal Growth Factor / Q000494:pharmacology*; D005796:Genes / Q000187:drug effects; D008854:Microscopy, Electron; D009857:Oncogenes; D014176:Protein Biosynthesis; D012313:RNA / Q000235:genetics*; D051381:Rats; D014158:Transcription, Genetic / Q000187:drug effects*
D004815:Epidermal Growth Factor; D012313:RNA; D004247:DNA; D004262:DNA Restriction Enzymes